Nytt datum för bokslutskommuniké

Nanologica senarelägger bokslutskommunikén till den 23 februari

Nanologica uppdaterar rapporteringskalendern och senarelägger bokslutskommunikén från den 16 februari till den 23 februari. Övriga rapporteringsdagar ligger kvar enligt tidigare.

För ytterligare information, vänligen kontakta: Andreas Bhagwani, VD i Nanologica Tel: +46 70 316 17 02 eller e-post andreas.bhagwani@nanologica.com

Se pressmeddelande

About us

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company’s mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.